HIMS — All updates

Being a leading telehealth company in the US could be a 10x, maybe even a bigger opportunity for Hims & Hers, but beating being the global telehealth company where you go to answer all your questions no matter where you are in the world is really where the massive opportunity is for healthcare and for Hims & Hers.

Number one, we're going to discuss Hims stock in this video, okay? There was some news that came out in regards to Hims. Stock went down heavy. I want to talk about that.

Hims stock got hammered here today, down 8% roughly, right? Tough day for Hims stock. Of the stocks on my watchlist, you know, 4000xstocks.com, that was the worst performer here today.

Hims & Hers, as for everything that it has gone through this year, is actually still down almost 20% for the year, but you can see shares bottomed in late February. Since then, up nearly 100% pulled back just a little bit.

They were trading at nearly $40 per share in early July. So, since then, down about 25%. Very volatile stock. So, something to keep in mind for investors.

But, there's is a stock that I've been interested in buying, and it's right on my watch list, and it is Hims. Hims stock, okay? This is one I've been interested in potentially starting a position, and it's 30, you know, just over $30 right now, right?

And I got it on my stocks to buy watch list, right?

today I've got Paul Cerro on for the second time. Paul runs Cedar Grove Capital and he has a thesis on Hims. The ticker is Hims.

He used to work for a Hims competitor, so he's got a you know, actual sector expertise and this is like he's done a write-up on This is his third time he's written up gone traded kind of quote-unquote traded the stock.

He went long the stock to great success. He went short the stock to great success and now he's long the stock again.